Research Briefs
What’s moving in peptide science — graded, weekly.
Each week we break down a new study, claim, or regulatory shift and tell you how strong the human evidence actually is. The opening is free for everyone; the full brief, sources, and archive are part of Vial+.
2026 · Week 24
Retatrutide, Explained in 60 Seconds: One Peptide, Three Hormone Targets
The investigational "triple agonist" posted some of the largest average weight reductions ever reported in an obesity trial — in Phase 2. Here's what that does and doesn't mean.
CagriSema and the Two-Hormone Bet: What the Phase 3 Data Actually Showed
Novo Nordisk paired a long-acting amylin analog with semaglutide and the market braced for a knockout. The late-2024 topline was more complicated than the headlines. Here is the evidence, graded.
Same Coffee, Different Clock: Why the Timing of Your Cup Showed Up in a Mortality Study
A large US study didn't ask how much coffee people drank — it asked when. The group that kept coffee to the morning showed a lower risk of death than all-day drinkers. The reason that's interesting is also the reason to read it carefully.
Three Ordinary Habits Nudged the Biological Clock — Here's What the Trial Actually Found
A randomized trial in adults over 70 tested vitamin D, omega-3, and a simple home workout against DNA 'aging clocks.' One intervention stood out — and the size of the effect is the part worth reading carefully.
Disclaimer: Research Briefs are educational and not medical advice. Evidence grades describe research maturity, not safety or suitability. Consult a licensed healthcare professional for personal decisions.